PD-02.08 : The efficacy and safety of tadalafil administered once a day for lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH) - 19/08/11
Doi : 10.1016/j.urology.2006.08.021
C.G. Roehrborn 1, K.T. McVary 2, J.D. Kaminestsky 3, S.M. Auerbach 4, B. Wachs 5, J.M. Young 6, A. Sesler 7, G.D. Sides 8, B.S. Denes 7
1 UT Southwestern Medical Center, Dallas, TX, USA
2 Northwestern University Medical School, Chicago, IL, USA
3 University Urology Associates, New York, NY, USA
4 California Professional Research, Newport Beach, CA, USA
5 Atlantic Urology Group, Long Beach, CA, USA
6 South Orange County Medical Resaerch Center, Laguna Woods, CA, USA
7 ICOS Corporation, Bothell, WA, USA
8 Eli Lilly and Company, Lilly Research Laboratories, Indianapolis, IN, USA
Le texte complet de cet article est disponible en PDF.
Plan
| Funded by Lilly ICOS LLC |
© 2006
Elsevier Inc. Tous droits réservés.
Vol 68 - N° S
P. 7-8 - novembre 2006 Retour au numéro
Article précédent
- PD-02.07 : Serum prostate-specific antigen is a predictor of the transition zone volume rather than total prostate volume in men with benign prostatic hyperplasia
- A.R. Zlotta, T. Ben Addi, C.C. Schulman, P. Rigatti, V. Scattoni, F. Montorsi
- PD-02.09 : Finasteride alone maintains stable urinary symptoms (ipss) in men with benign prostatic hyperplasia after 9 months of combination therapy using an alpha-blocker and finasteride
- M. Elhilali, C. Dupont, C. Koch, PROACT study centers
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?